ART Interruption During Primary vs. Chronic Infection

In an observational study, times to viral rebound and CD4-cell decay were slightly longer when treatment interruption occurred during primary infection than when it occurred during chronic infection.

The SMART trial clearly demonstrated that treatment interruption during chronic HIV infection results in CD4-cell decline, prompt viral rebound, and, when compared with continuous antiretroviral therapy (ART), an increased risk for clinical events (AIDS Clin Care Nov 29 2006). Uncertainty remains, however, about the outcomes associated with temporary treatment during primary infection and about whether such treatment can positively influence the viral set point.

Using data from two prospective studies, researchers compared outcomes of single treatment interruptions in 24 patients who started ART during primary infection and 46 who started ART during chronic infection at CD4 counts ≥350 cells/mm³. At the time of treatment interruption, all th…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

ART Interruption During Primary vs. Chronic Infection

Topics

Reviewing Author